Via is a re-engineering public transit company that develops and provides on-demand public mobility solutions for commuters. The company transforms public transit, from a regulated system of rigid routes and schedules to a fully dynamic, on-demand network. Via's mobile app connects passengers who are headed the same way, allowing riders to seamlessly share a premium vehicle.
The platform operates in the United States and in Europe through its joint venture with Mercedes-Benz Vans, ViaVan. Via's technology is deployed worldwide through partner projects with public transportation agencies, private transit operators, taxi fleets, private companies, and universities, integrating with public transit infrastructure to power cutting-edge on-demand mobility.
The company was founded in 2012 and is headquartered in New York, United States.
IntelyCare offers a digital workforce augmentation platform that combines a gig-model application with advanced data science to optimize staff resources and close the widening gap between workforce supply and demand. IntelyCare is revolutionizing the antiquated healthcare staffing market, filling nursing shifts at three times the industry average and giving post-acute facilities the tools to predict and manage staffing needs. The company’s engaging mobile app empowers nursing professionals with access to flexible, on-demand work opportunities, reducing burnout and attrition while increasing productivity.
22seventy bio is an immuno-oncology cell therapy company that discovers and develops cancer therapies. The company combines a deep knowledge of cancer cell biology and genetics with an understanding of the immune response to cancer to advance its pipeline. It was established in Cambridge, Massachusetts in 2021.
Magnolia Medical Technologies, Inc. is a Seattle-based company that specializes in the development and manufacturing of medical devices aimed at enhancing the accuracy of diagnostic blood culture tests. Its flagship product, SteriPath, is a vacuum-assisted blood collection system designed to divert contaminants from the initial blood sample, thereby reducing the incidence of blood culture sample contamination. The company markets its products through distributors across the United States and has built a robust intellectual property portfolio, consisting of over 70 issued patents and more than 50 pending applications. Founded in 2011, Magnolia Medical Technologies is committed to improving diagnostic specimen quality and increasing the accuracy of critical laboratory tests.
Inspirato LLC is a luxury hospitality company based in Denver, Colorado, that offers its members access to a curated collection of high-end vacation residences, villas, and premium hotel accommodations. Founded in 2010 and rebranded in 2013, Inspirato serves over 10,000 members by providing a variety of vacation options in desirable destinations worldwide, including beach, mountain, and metropolitan areas. The company operates under an innovative club model, ensuring that members receive personalized recommendations, expert planning, and on-site concierge services. Inspirato's portfolio includes managed residences for exclusive member use, featuring world-class amenities and competitive pricing. The company has also partnered with American Express to enhance its offerings, aligning with shared values of luxury and service.
Parse Biosciences, based in Seattle, Washington, focuses on single-cell analysis and was incorporated in 2018. The company is dedicated to developing innovative technologies that enhance the understanding of cellular diversity and function at the single-cell level. By leveraging advanced methodologies, Parse Biosciences aims to provide researchers with powerful tools for exploring complex biological systems, ultimately advancing the fields of genomics and biomedical research.
Loadsmart, Inc. operates an online platform designed to streamline the logistics process for shippers and carriers. Founded in 2014 by Felipe Capella and Ricardo Salgado, the company is headquartered in New York, with an additional office in Chicago. The platform offers users the ability to obtain real-time, bookable rates, facilitating efficient interactions between shippers and carriers. It allows shippers to quickly move freight and helps carriers optimize their capacity by keeping trucks full. Loadsmart's service includes features for obtaining quotes, booking trucks, and tracking freight from pickup to delivery, thereby enhancing the overall efficiency of the shipping process.
Silagene is a biotech company developing technology designed to facilitate the creation of U1 adaptors with therapeutic potential. The company's technology overcomes the limitations of gene silencing technologies, enabling doctors to to treat patients with various types of cancers.
It was founded in 2008 and is based in Hillsborough, New Jersey, United States.
Enliven Therapeutics is a precision oncology company developing small molecule therapies to extend and improve patient lives. The company's discovery process combines clinically validated biological targets and industry-leading chemistry to address the limitations of existing therapies. This approach allows us to efficiently and effectively develop precision oncology therapeutics that enhance overall patient well-being.
Curevo Vaccine is clinical stage biotech company dedicated to developing next generation vaccines that bring effectiveness, safety, tolerability, and advanced production capabilities to the market - quickly and efficiently. Curevo's lead product, a sub-unit Zoster (Shingles) Vaccine, has completed Phase I (90 subject trial). Results are showing a promising safety profile and the desired immune responses. We are targeting a unique position in the $7B Varicella Zoster Virus vaccine market.
Grab Holdings Inc. is a Singapore-based company that offers a comprehensive mobile technology platform providing various online-to-offline services in Southeast Asia. Founded in 2012 by Anthony Tan and Tan Hooi Lng, Grab operates in several countries, including Singapore, Indonesia, the Philippines, Malaysia, Thailand, Vietnam, and Myanmar. The platform includes a wide range of services such as transportation options like GrabTaxi and GrabCar, and delivery services, alongside solutions for financial transactions through Grab Financial Group. This group provides services in payments, rewards, lending, and insurance, and features a user-friendly point-of-sale system for merchants, as well as a mobile wallet for convenient transactions. Grab aims to enhance the quality of life for its users by integrating essential services into a single app.
Via is a re-engineering public transit company that develops and provides on-demand public mobility solutions for commuters. The company transforms public transit, from a regulated system of rigid routes and schedules to a fully dynamic, on-demand network. Via's mobile app connects passengers who are headed the same way, allowing riders to seamlessly share a premium vehicle.
The platform operates in the United States and in Europe through its joint venture with Mercedes-Benz Vans, ViaVan. Via's technology is deployed worldwide through partner projects with public transportation agencies, private transit operators, taxi fleets, private companies, and universities, integrating with public transit infrastructure to power cutting-edge on-demand mobility.
The company was founded in 2012 and is headquartered in New York, United States.
Quell's vision is to become a leading engineered Treg cell therapy company. The company will seek to develop next generation engineered T-regulatory cell (Treg) therapies for a range of solid organ transplant and autoimmune conditions. Quell has been founded by Syncona in partnership with six leading experts in the Treg field, cell engineering, solid organ transplantation and autoimmune diseases: Giovanna Lombardi, Professor of Human Transplant Immunology at Kings College London (KCL), Alberto Sanchez-Fueyo, Professor of Hepatology in the Institute of Liver Studies at KCL, Hans Stauss, Professor of Tumour Immunology and Director of the Institute of Immunity and Transplantation at University College London (UCL), Emma Morris, Professor of Clinical Cell & Gene Therapy and Inflammation, Immunity and Immunotherapeutics Theme Director, National Institute for Health Research University College London Hospitals Biomedical Research Centre, Marc Martinez-Llordella, Senior Lecturer in the Institute of Liver Studies at KCL and Elmar Jaeckel, Co-Leader Liver Transplant program MHH, Group Leader "Immune tolerance" in the Department of Gastroenterology, Hepatology and Endocrinology at Hannover Medical School.
Chroma Medicine is a new genomic medicine company working on epigenetic editing. Chroma Medicine is pioneering a new class of genomic medicines that harness epigenetics, nature’s innate mechanism for gene regulation, to revolutionize the treatment of genetically driven diseases.
Shoreline Biosciences is a biomedical company intended to establish immunotherapies for seriously ill patients. Its proprietary cell therapy technology platform is based on deep expertise in iPSC differentiation methods and genetic programming of the IL-15/CISH pathway for enhanced metabolic fitness and persistence of the engineered NK Cells to improve anti-cancer activity.
The company was founded in 2020 and is headquartered in La Jolla, CA, USA.
Cedilla is a developer of therapeutics technologies intended to broaden the reach of small molecule therapeutics. The company's technology is focused on destabilizing oncoprotein targets that are also applicable to therapies outside of oncology, enabling doctors to treat diseases caused by protein dysregulation.
The company was founded in 2018 and based in Cambridge, Massachusetts.
PharmEasy is a leading pharmacy aggregator in India that operates an online drug delivery platform aimed at enhancing the supply chain of pharmaceuticals. By digitizing the process, it connects patients with local pharmacy stores and diagnostic centers, ensuring they can easily access a wide range of medicines and healthcare products. The platform is designed to make healthcare services more accessible and affordable, emphasizing the importance of good health for everyone. Through its services, PharmEasy strives to simplify the healthcare experience for patients, allowing them to fulfill their medical needs efficiently.
Wallbox Chargers S.L., commonly known as Wallbox, specializes in the design, manufacture, and distribution of charging solutions for electric and hybrid vehicles, catering to both residential and commercial markets. Established in 2015 and headquartered in Barcelona, Spain, the company has developed a robust portfolio that includes intelligent charging solutions utilized by major automotive manufacturers and large electric utilities. Wallbox operates a manufacturing facility in Barcelona with an annual production capacity of 500,000 chargers, supported by a skilled engineering team. Additionally, the company manages the development of its charging management platform, myWallbox, and provides after-sales support from its Madrid office. Wallbox has expanded its presence internationally with subsidiaries in several countries, including Germany, the United Kingdom, the Netherlands, France, the United States, and China. In China, Wallbox has formed a joint venture, Wallbox FAWSN Charging Systems Co Ltd., which includes a production plant dedicated to serving the local market.
Ventyx Biosciences, Inc. is a biotechnology company based in Encinitas, California, focused on developing selective inhibitors of TYK2 for the treatment of autoimmune diseases. Incorporated in 2018, the company boasts a diverse portfolio of innovative clinical and pre-clinical programs aimed at high-value therapeutic targets. Through its research and development efforts, Ventyx is committed to advancing treatments that address unmet medical needs in the autoimmune disease space.
LEXEO Therapeutics is a fully integrated biotechnology company. LEXEO Therapeutics’ pipeline consists of adeno-associated virus (AAV)-mediated therapies primarily developed at Weill Cornell Medicine’s Department of Genetic Medicine. Beyond LEXEO Therapeutics’ lead programs – which are focused on both rare and non-rare monogenic (single genemutation) diseases – the company’s preclinical pipeline spans monogenic diseases, as well as hereditary and acquired diseases across a spectrum of patient population sizes and a range of unmet medical needs. Importantly, LEXEO Therapeutics will focus on advancing clinical programs through to commercialization, with the goal of maintaining an ongoing research collaboration with Weill Cornell Medicine’s Department of Genetic Medicine to help advance the company’s pre-clinical pipeline.
Attralus is a biopharmaceutical company focusing on creating transformative medicines to improve the lives of patients with systemic amyloidosis. Its proprietary peptide-based pan-amyloid targeting agents have the potential to diagnose and treat all forms and stages of systemic amyloidosis. The company is focused on targeting common pathology in all systemic amyloidosis diseases, with the goal of developing treatments for all subtypes of amyloidosis, including the majority in which there are currently no treatment options.
Disc Medicine, Inc. is a biotechnology company focused on developing therapeutics based on human genetics to address ineffective red blood cell production in hematologic diseases. The company specializes in programs targeting the hepcidin metabolism axis for the treatment of disorders related to hepcidin. Founded in 2017 and headquartered in Cambridge, Massachusetts, Disc Medicine is led by a team of experienced scientists and industry experts, supported by a panel of advisors with a proven history in discovering and developing innovative therapies. The company was established with backing from Atlas Venture, along with contributions from Novo Ventures and Access Biotechnology.
SomaLogic operates as a protein biomarker discovery and clinical diagnostics company. It offers SOMAmers (Slow-Offrate Modified Aptamers), which are modified nucleic acid-based protein-binding reagents that are specific for their cognate protein; and SOMAscan that provides protein detection and equipment. The company’s SOMAmer/SOMAscan technology enables to discover protein biomarker signatures; drug discovery and development; and clinical diagnostics. Its products have applications in the diagnostics of various diseases in oncology, neurology, cardiovascular and metabolic disease, and other diseases and conditions.
SomaLogic was founded in 1999 and is headquartered in Boulder, Colorado.
Asher Biotherapeutics, Inc. is a biotechnology company focused on developing immunotherapy drugs for cancer treatment. Founded in 2019 and headquartered in South San Francisco, California, the company aims to create innovative therapeutic solutions to improve patient outcomes in oncology. Asher Bio leverages advanced technologies and research to enhance the effectiveness of immune-based therapies, positioning itself as a key player in the evolving field of cancer treatment.
DiCE Therapeutics, founded in 2013 and based in Menlo Park, California, specializes in developing a platform for the discovery of novel small molecules aimed at targets that have previously been difficult to address in the pharmaceutical sector. The company utilizes innovative technology that extends directed evolution, allowing for the direct translation of DNA-encoded information into organic compounds, thereby streamlining the traditionally labor-intensive processes of medicinal chemistry. This platform not only serves the pharmaceutical industry but also has applications in agriculture and materials sciences. The founding team includes notable figures such as Stanford Professor Pehr Harbury, who developed the core technology, and other experienced professionals from various sectors, contributing to the company's mission of transforming drug discovery and development.
Xos Trucks Inc. operates as a transportation lab making electric commercial vehicle fleets and battery-electric vehicle platforms. It helps commercial fleets transition from diesel to zero-emission electric delivery vehicles with the same performance but lower operating costs. The company also develops electrified armored cars. It delivers trucks to Texas and Illinois, with future customers in Michigan and New Jersey. Xos Trucks Inc. was formerly known as Thor Trucks and changed its name to Xos Trucks Inc. in April 2019. The company was founded in 2016 and is based in North Hollywood, California.
Tango Therapeutics, Inc., a biotechnology company, develops cancer drugs based on synthetic lethality. The company uses the genetic principle of synthetic lethality to discover and develop therapies that take aim at driver genes in cancer. It focuses counteracting tumor suppressor gene loss; reversing the ability of cancer cells to evade the immune system; and identifying novel combinations that are more effective than single agent therapy. Tango Therapeutics, Inc. was formerly known as Cancer Combos NewCo, Inc. The company was incorporated in 2014 and is based in Cambridge, Massachusetts.
Sonoma Biotherapeutics is a company invloved the development of adoptive Treg therapies cell for autoimmune and degenerative diseases. Using next generation genome editing and target-specific cell therapy, Sonoma is focused on developing its best-in-class platform across the entire spectrum of Treg cell therapeutic capabilities. Founded by pioneers in Treg biology and cell therapy, the company brings together leading expertise and proprietary methodologies for the discovery and development of disease modifying and curative therapies.
CCC Drive, based in Glen Allen, Virginia, provides a versatile technology platform for insurance telematics, known as DriveFactor. This platform allows for the integration of data from various sources and facilitates sharing with business partners. CCC Drive enables clients to manage the entire claims process, including intake, evaluation, settlement, and optimization. The company, originally founded in 2010 as DriveFactor Inc., became a subsidiary of CCC Information Services Inc. in 2015. CCC Information Services focuses on enhancing claims management through integrated solutions, offering advanced collision repair and insurance estimating software, analytical tools, and data services. Their technology improves efficiency across the claims management supply chain, fostering communication among a network of approximately 21,000 auto body collision repair facilities and 350 insurance companies.
Owlet Baby Care Inc. is a company that develops and manufactures innovative monitoring products designed to track the vital signs of sleeping infants. Founded in 2012 and based in Lehi, Utah, Owlet offers the Owlet Smart Sock, a device that monitors an infant's heart rate and oxygen levels, alerting parents if there are any concerns. The Owlet Baby Monitor provides real-time data on a child's vital signs through a compatible app for iOS and Android devices, giving parents peace of mind. The company's product range also includes the Owlet Cam, which transforms smartphones into high-definition baby monitors, and the Owlet Monitor Duo, which combines the features of the Smart Sock with the Cam. Additionally, the Owlet Dream Lab offers resources to help parents establish healthy sleep habits for their children. Owlet's commitment to enhancing parental confidence through technology is reflected in its diversified product portfolio.
Element Biosciences, Inc. develops genetic analysis tools for the research and diagnostic markets. The company provides a disruptive DNA sequencing technology and a sequencing platform, such as surface chemistry, sequencing chemistry, detection, and data analysis. The company was incorporated in 2017 and is based in San Diego, California.
Synthekine Inc. is a biotechnology company focused on developing innovative cytokine therapies and immunotherapies for cancer and autoimmune disorders. Founded in 2018 and based in Menlo Park, California, the company leverages advanced platform technologies, including engineered partial agonists and orthogonal cell therapies, to create targeted treatments. Synthekine's notable innovations include the Synthekine Platform, which utilizes surrogate agonists instead of traditional mutant cytokines. The company's product pipeline features STK-009, an orthogonal ligand paired with SYNCAR-001, an engineered CAR-T therapy targeting CD-19, as well as STK-012, a partial agonist of IL-2. Synthekine's approach emphasizes safety and efficacy, utilizing immunological insights to guide the development of therapeutics that selectively modulate immune system pathways. Preclinical studies have indicated promising efficacy and tolerability for its lead programs, positioning Synthekine as a key player in the biotechnology landscape.
BioTheryX, Inc. is a biopharmaceutical company based in Chappaqua, New York, that specializes in the development of therapies for hematological malignancies and other diseases. The company focuses on restoring protein homeostasis through innovative approaches such as Protein Homeostatic Modulators, which are small molecular glue cereblon binders with significant therapeutic potential. Additionally, BioTheryX is advancing targeted protein degradation technologies, including PROTACs, which utilize dual ligands to facilitate the degradation of specific proteins. The company also offers BTX-A51, an oral small molecule that acts as a multi-kinase inhibitor to target leukemic stem cells and suppress key oncogenic gene transcription. Founded in 2007, BioTheryX aims to expedite the delivery of effective therapies to patients with unmet medical needs by leveraging enhanced biology-driven models and clinically proven translational approaches.
Magenta is focused on improving the patient experience in transplant medicine, with the goal of bringing this lifesaving procedure to more patients. Over the past 50 years, stem cell transplantation has been used in more than 1M patients worldwide. It is currently the only treatment with the potential to cure some of the most devastating hematologic cancers and autoimmune diseases. Despite the increased use and clinical advancements over the past several decades, stem cell transplant remains a high-risk last-resort therapeutic option due to the toxicity and potential long-term side effects.
Nuvalent is a biotechnology company that develops targeted therapies for clinically proven kinase targets in cancer. Leveraging deep expertise in structure-based design, Nuvalent develops innovative small molecules with exquisite target selectivity to overcome resistance, minimize adverse events, and drive more durable responses. It is advancing a robust pipeline with parallel lead programs in ROS1-positive and ALK-positive NSCLC, along with multiple discovery-stage research programs. It was founded in 2017 and is based in Cambridge, Massachusetts.
TwinStrand Biosciences, Inc. is a biotechnology company that specializes in Duplex Sequencing, a technology that significantly enhances the accuracy of DNA sequencing by over 10,000 times. This advanced method enables the detection of ultra-low frequency genomic variants that are often overlooked by conventional sequencing techniques. Founded in 2015 and based in Bellevue, Washington, TwinStrand's technology has diverse applications across various fields, including oncology, infectious disease, organ transplantation, reproductive and genetic health, and forensics. The company's innovative approach provides researchers and clinicians with essential data to inform critical decisions in clinical medicine and public health, facilitating quicker and clearer insights into complex genetic information.
NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States, as well as laboratories in Switzerland and Singapore. It operates in two segments, Clinical Services and Pharma Services. The company’s laboratories provide genetic and molecular testing services to hospitals, pathologists, oncologists, urologists, other clinicians and researchers, pharmaceutical firms, academic centers, and other clinical laboratories. It offers cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fluorescence in-situ hybridization testing services that focus on detecting and locating the presence or absence of specific DNA sequences and genes on chromosomes; flow cytometry testing services to measure the characteristics of cell populations; immunohistochemistry and digital imaging testing services to localize proteins in cells of a tissue section, as well as to allow clients to see and utilize scanned slides, and perform quantitative analysis for various stains; and molecular testing services, which focus on the analysis of DNA and RNA, and the structure and function of genes at the molecular level. The company also provides morphologic analysis which is the process of analyzing cells under the microscope by a pathologist for the purpose of diagnosis; and testing services in support of its pharmaceutical clients’ oncology programs covering discovery and commercialization, as well as acts as a reference laboratory supplying anatomic pathology testing services. NeoGenomics, Inc. has a strategic collaboration with Inivata Limited for the commercialization of its InVisionFirst-Lung liquid biopsy test in the United States. NeoGenomics, Inc. was founded in 2001 and is headquartered in Fort Myers, Florida.
Janux Therapeutics develops immunotherapies that generate immune responses to prevent tumors and not affecting a patient’s healthy tissue. Janux technology targets all three stages of the anti-tumor immune response. Janux Therapeutics, Inc. was founded in 2017 by David Campbell and is based in La Jolla, California.
ValenzaBio is developing safe and effective treatment options for patients with autoimmune and inflammatory diseases. ValenzaBio implements biomarker-driven approaches to guide research and clinical development. Our pipeline includes several monoclonal antibodies targeting surface antigens to reduce pathogenic subpopulations of autoreactive cells. Our most advanced program has generated Phase 1 proof-of-concept in patients and we’re progressing preclinical programs focused on differentiated mechanisms of action. Our mission is to provide safe and effective treatment options for patients with unmet needs.
Icosavax is focused on developing safe and effective vaccines against infectious diseases that address important unmet medical needs and reduce healthcare costs. tHEY were founded on breakthrough computationally-designed virus-like particle technology, exclusively licensed for a variety of infectious disease indications from the Institute for Protein Design at the University of Washington.
Tyra Biosciences is a clinical-stage biotechnology company based in Carlsbad, California, focused on developing small molecule therapies for cancer treatment. Founded in 2018, the company aims to address drug resistance in oncology by targeting specific pathways associated with acquired resistance. Tyra Biosciences employs its proprietary precision medicine platform, SNÅP, to facilitate rapid drug design through molecular snapshots, enabling the prediction of genetic alterations that may lead to resistance against existing therapies. The company's lead product candidate, TYRA 300, is an FGFR3 selective inhibitor, primarily aimed at treating patients with metastatic urothelial carcinoma of the bladder and urinary tract. Through innovative approaches, Tyra Biosciences seeks to create next-generation precision medicines that significantly improve treatment outcomes for cancer patients.
At Graphite Bio, they are rapidly building a next-generation gene editing company that is driven to apply their breakthrough technology with urgency to advance gene replacement therapies and cures for people living with serious diseases. They stand apart through our ability to harness natural and highly precise cellular DNA repair machinery to achieve high efficiency, targeted gene integration to correct the underlying causes of diseases.
Amunix Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to discovering and developing innovative protein and peptide therapeutics for cancer treatment. The company specializes in creating prodrugs that leverage its proprietary XTEN half-life extension platform, XPAT technology for analyzing protease activity in tumor environments, and ProTIA, an immuno-oncology therapeutic. Amunix aims to harness the immune system to develop safe and effective therapies for patients with solid tumors. The company collaborates with various academic, biotechnology, and pharmaceutical sectors, establishing strategic partnerships with several prominent organizations in the industry. Founded in 2006 and based in Mountain View, California, Amunix continues to advance its pipeline of novel biologics, focusing on improving treatment outcomes for cancer patients.
DTx Pharma, LLC is a biotechnology company focused on developing and commercializing fatty acid-conjugated peptide therapeutics aimed at treating patients with rare and chronic diseases globally. The company utilizes innovative technology to enhance the delivery of RNA medicines to various tissues and organ systems, effectively addressing limitations faced by earlier platforms, such as poor pharmacokinetics and inadequate cellular uptake. DTx Pharma's therapies target conditions including retinitis pigmentosa, Duchenne muscular dystrophy, and central nervous system disorders. Founded in 2017, the company is headquartered in San Diego, California.
Artiva Biotherapeutics, Inc., a biotech company, develops and manufactures cellular immunotherapies for cancer patients. The company offers a pipeline of off-the-shelf, allogeneic natural killer (NK) cell therapies for the treatment of hematologic cancers or solid tumors. The company’s products target CD20 and CD19 in B-cell lymphomas and HER2 in various solid tumors. The company was founded in 2019 and is headquartered in San Diego, California. Artiva Biotherapeutics, Inc. operates as a subsidiary of Green Cross Holdings Corporation.
Viracta Therapeutics specializes in developing innovative treatments for cancers linked to the Epstein-Barr Virus. The company is advancing its proprietary viral gene activation therapy, which aims to effectively target and address these virus-associated malignancies. In addition to its primary focus on Epstein-Barr Virus-related cancers, Viracta is also exploring opportunities to tackle other serious diseases associated with viral infections. Through its research and therapeutic advancements, the company seeks to improve outcomes for patients suffering from these challenging health conditions.
Centessa Pharmaceuticals is a next-generation biopharmaceutical company that aims to reshape the traditional drug development process. The company applies an asset-centric R&D model at scale to advance a portfolio of highly validated programs led by industry-leading teams. Each program is developed by a Centessa Subsidiary and supported by a centralized infrastructure and the Centessa management team.
Cyteir is developing the next generation of synthetic lethal therapies to treat cancer.Cyteir Therapeutics is creating breakthrough solutions to the major challenges facing cancer researchers today. Currently in development, is the answer to the oncology triumvirate: reducing side effects, reducing therapy resistance, inducing diseased cell self destruction.
HemoShear Therapeutics develops new treatments for patients with rare metabolic disorders. It creates human-relevant systems to accurately replicate the biology of organ systems and diseases for use throughout drug discovery and development. They work strategically in partnerships with pharmaceutical, biotechnology, and medical device companies. It generates meaningful human response data to increase confidence in decision-making, reduce the risk of costly failures, and identify efficacious therapies.
Day One Biopharmaceuticals is a biotechnology company focused on developing new cancer therapies for patients of all ages. The company understands that advances in cancer research now enable drug developers to identify children and adults who may benefit from the same medicine. They develop new therapies that meet the critical needs of people of all ages living with cancer starting from the biology of childhood cancer. Day One Biopharmaceuticals also focuses its efforts to bring the best medicines to families receiving the life-altering news of a new cancer diagnosis and the need for a treatment plan. It prioritizes programs that can be rapidly brought to market for both younger and older patients. The company's goal is to license and acquire the most promising products from research institutions as well as for biotechnology and pharmaceutical companies. Day One Biopharmaceuticals was founded in 2018 and is headquartered in South San Francisco, CA, USA.
Shoreline Biosciences is a biomedical company intended to establish immunotherapies for seriously ill patients. Its proprietary cell therapy technology platform is based on deep expertise in iPSC differentiation methods and genetic programming of the IL-15/CISH pathway for enhanced metabolic fitness and persistence of the engineered NK Cells to improve anti-cancer activity.
The company was founded in 2020 and is headquartered in La Jolla, CA, USA.
Inivata is a clinical cancer genomics company harnessing the emerging potential of circulating DNA analysis to improve testing and treatment for oncologists and their patients.
Unlike conventional invasive biopsies, Inivata detects and analyses genomic material from a cancer patient’s cell-free, circulating tumour DNA (ctDNA) which can be collected through a simple blood sample. This non-invasive approach – a liquid biopsy – offers a revolution in how cancer is detected, monitored and treated.
Design Therapeutics, Inc. develops therapies for the treatment of degenerative disorders caused by nucleotide repeat expansions. The company engages in the development of a program for the treatment of Friedreich’s ataxia and degenerative diseases such as Fragile X syndrome and myotonic dystrophy. The company was incorporated in 2017 and is based in Solana Beach, California.
Verve Therapeutics, Inc. is a biotechnology company focused on developing innovative therapies aimed at editing the adult human genome to reduce the risk of coronary artery disease, a leading cause of death globally. Founded in 2018 and headquartered in Cambridge, Massachusetts, with a research facility in Philadelphia, the company leverages human genetic analysis and gene-editing technologies to create treatments that offer lifelong protection from this condition. Verve has established strategic alliances, including collaborations with Beam Therapeutics to advance delivery technologies targeting cardiovascular issues and with Verily for developing gene editing delivery vehicles. Formerly known as Endcadia, Verve Therapeutics rebranded in September 2019 to reflect its commitment to addressing heart disease through advanced genetic solutions.
New Amsterdam Pharma B.V. is a clinical-stage biopharmaceutical company based in Naarden, the Netherlands, focused on researching and developing innovative therapies for cardio-metabolic diseases. Founded in 2019, the company is dedicated to improving patient care for those with metabolic disorders, particularly where existing treatments are inadequate or poorly tolerated. Its lead product, obicetrapib, is a next-generation oral CETP inhibitor designed to provide a preferred LDL cholesterol-lowering option for patients who experience statin intolerance or for those with Arteriosclerotic Cardiovascular Disease and Familial Hypercholesterolemia who are on maximally tolerated statin therapy.
LEXEO Therapeutics is a fully integrated biotechnology company. LEXEO Therapeutics’ pipeline consists of adeno-associated virus (AAV)-mediated therapies primarily developed at Weill Cornell Medicine’s Department of Genetic Medicine. Beyond LEXEO Therapeutics’ lead programs – which are focused on both rare and non-rare monogenic (single genemutation) diseases – the company’s preclinical pipeline spans monogenic diseases, as well as hereditary and acquired diseases across a spectrum of patient population sizes and a range of unmet medical needs. Importantly, LEXEO Therapeutics will focus on advancing clinical programs through to commercialization, with the goal of maintaining an ongoing research collaboration with Weill Cornell Medicine’s Department of Genetic Medicine to help advance the company’s pre-clinical pipeline.
Scorpion Therapeutics, Inc. is a biotechnology company based in Boston, Massachusetts, focused on developing advanced precision oncology therapies for cancer treatment. Founded in 2020, the company aims to enhance the accessibility and effectiveness of precision medicine for cancer patients. Scorpion Therapeutics specializes in creating drugs in three primary areas: therapies targeting known oncogenes, agents for currently undruggable cancer targets, and innovative drugs for new targets. By integrating state-of-the-art technologies in target discovery, medicinal chemistry, and translational medicine, the company is committed to delivering next-generation precision oncology solutions. Its experienced leadership team is dedicated to employing a tailored approach to efficiently advance the field of precision cancer treatment.
Biomea Fusion is a privately held precision medicine company with a mission to revolutionize drug development to create more effective therapies for cancer patients. Biomea Fusion has a development portfolio that targets specific gene alterations which occur in the DNA of patients that translate into key drivers of tumor growth. It is Biomea’s goal to move these potentially breakthrough medicines swiftly through the development process and deliver highly impactful treatments for patients in need. The lead program targets the protein-to-protein interaction between menin and the MLL complex for the treatment of various tumors.
SomaLogic operates as a protein biomarker discovery and clinical diagnostics company. It offers SOMAmers (Slow-Offrate Modified Aptamers), which are modified nucleic acid-based protein-binding reagents that are specific for their cognate protein; and SOMAscan that provides protein detection and equipment. The company’s SOMAmer/SOMAscan technology enables to discover protein biomarker signatures; drug discovery and development; and clinical diagnostics. Its products have applications in the diagnostics of various diseases in oncology, neurology, cardiovascular and metabolic disease, and other diseases and conditions.
SomaLogic was founded in 1999 and is headquartered in Boulder, Colorado.
Apartment List is a smart, simple, and seamless renting platform that’s dedicated to making the process fair and transparent for all. Their mission is to build a better world of renting for everyone, to get rid of the pain and complexity, and makes it more personal, flexible, and transparent.
They make finding a home to love easy and enjoyable, with a personally curated search feature that gets to know the individual.
It was incorporated in 2009 and is based in San Francisco, California.
Edgewise Therapeutics is a clinical-stage biopharmaceutical company based in Boulder, Colorado, specializing in the development of small molecule therapies for severe musculoskeletal diseases. Founded in 2017, the company leverages its expertise in skeletal muscle physiology to create innovative treatments for genetically defined muscle disorders, including Duchenne, Becker, and limb girdle muscular dystrophies. Edgewise Therapeutics employs a precision medicine platform to identify and target key muscle proteins and modulators, aiming to address the underlying causes of these conditions. Additionally, the company has established a state-of-the-art research facility to enhance its capabilities in understanding muscle adaptation and injury related to disease.
QuantumScape is a renewable energy company focused on advancing solid-state battery technology to enhance the performance and range of electric vehicles. Founded in 2010 by Jagdeep Singh in San Jose, California, the company aims to transform the battery industry by creating a solid-state battery that offers significantly higher energy storage capacity compared to traditional batteries. QuantumScape is developing next-generation solid-state lithium-metal batteries, featuring an innovative anode-less cell design that improves energy density while reducing material costs and streamlining manufacturing processes. Through these advancements, QuantumScape seeks to facilitate the widespread adoption of electric vehicles.
Elevation Oncology, Inc. is a biotechnology company dedicated to creating precision medicines for patients with genomically defined cancers. Founded in 2019 and headquartered in New York, the company focuses on developing targeted therapies that inhibit specific genetic alterations associated with cancer progression. Its lead candidate, seribantumab, is designed to address tumor growth driven by NRG1 fusions and is currently undergoing clinical evaluation in the Phase 2 CRESTONE study, which includes patients with various tumor types exhibiting this genomic alteration. Through its innovative approach, Elevation Oncology aims to enhance treatment options for individuals with solid tumors linked to specific genetic drivers.
Decibel Therapeutics is a clinical-stage biotechnology company dedicated to discovering and developing therapies aimed at protecting, repairing, and restoring hearing. The company focuses on a range of hearing disorders, including those related to cancer treatments, cystic fibrosis, noise exposure, age-related and genetic hearing loss, as well as tinnitus. It utilizes advanced techniques such as single-cell genomics, bioinformatics, and precision gene therapy technologies to enhance its understanding of inner ear pathology and to develop effective treatments. Decibel Therapeutics also offers expertise in drug delivery to the inner ear, imaging, and pharmacokinetic modeling, contributing to innovative therapeutic approaches for patients experiencing various forms of hearing loss. Founded in 2013 and based in Boston, Massachusetts, Decibel Therapeutics was previously known as Hearing, Inc. before rebranding in 2014.
Olema Oncology is a clinical-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of therapies for women's cancers, particularly focusing on estrogen receptor-positive breast cancer. The company's lead candidate, OP-1250, is an estrogen receptor antagonist and selective degrader, currently undergoing Phase 1/2 clinical trials for the treatment of metastatic or locally advanced, estrogen receptor-positive, and human epidermal growth factor receptor 2-negative breast cancer. Olema Oncology aims to innovate targeted therapies by leveraging its expertise in endocrine-driven cancers and mechanisms of acquired resistance. The company seeks to enhance treatment options for both pre- and post-menopausal women with breast cancer, striving to transform the standard of care with more effective and convenient therapies. Founded in 2006 and headquartered in San Francisco, California, Olema was previously known as CombiThera, Inc. and rebranded in 2009.
Flame Biosciences, Inc operates as a clinical stage company that engages in the research, development, and commercialization of transformative therapies for cancer and other inflammatory conditions. It offers FL-101 therapy for the treatment of lung cancers that are driven by inflammation; and FL-201 for reducing the chronic inflammation in patients. The company was incorporated in 2017 and is based in New York, New York.
Galecto, Inc. develops small molecules for the treatment of severe diseases, including fibrosis and cancer. The company, founded in 2011, builds on more than 10 years of research centering on the role of galectin-3 and LOXL-2, and the use of modulators of these proteins to treat fibrosis-related diseases and cancer. Combined with a strong patent estate, these assets give Galecto a unique therapeutic platform.
Eledon Pharmaceuticals, Inc. is a specialty pharmaceutical company dedicated to developing products for patients with ear, nose, and throat disorders. The company's lead product, OP0201, is a surfactant-based nasal aerosol designed for individuals at risk of or suffering from otitis media, which is inflammation of the middle ear. In addition to OP0201, Eledon has developed foam-based drug delivery technologies, OP0101 and OP0102, aimed at administering medications to the ear, nose, and sinus cavities. Founded in 2004 and initially known as Novus Therapeutics, the company rebranded in January 2021 and is headquartered in Irvine, California.
Rain Therapeutics Inc. is a biotechnology company focused on developing targeted therapies for cancer patients, particularly those with unmet medical needs. Established in 2017 and based in Newark, California, the company specializes in small molecule therapeutics. Its lead product, RAIN-32, is a small molecule MDM2 inhibitor aimed at treating well-differentiated and de-differentiated liposarcoma. Additionally, Rain Therapeutics is developing tarloxotinib, a hypoxia-activated pan-HER inhibitor currently undergoing clinical trials for non-small cell lung cancer. The company emphasizes identifying cancers driven by specific oncogenic mutations and evaluates sub-populations where existing treatment options are inadequate. Through collaboration with a global network of scientific and thought leaders, Rain Therapeutics seeks to align its therapeutic innovations with the needs of these cancer populations.
Kinnate Biopharma develops precision oncology therapeutics to treat patients with genomically-defined cancers. Its mission is to expand the reach of targeted therapeutics by developing products for underserved populations.
The company utilizes its deep expertise in structure-based drug discovery, translational research, and patient-driven precision medicine. Its programs include candidates in preclinical development for cancers that are driven by specific oncogenic alterations in either the BRAF kinase gene or in the FGFR2 and FGFR3 kinase genes.
Chinook Therapeutics is a biotechnology company that specializes in the fields of therapeutics and life science. The company focuses on developing precision medicines for kidney diseases. Its services offers utilization of novel translational platforms and patient stratification tools, and emergence of accelerated regulatory pathways based on surrogate endpoints.
The company was founded in 2019 and headquartered in Alberta, Canada.
Thrive Earlier Detection Corp. is a healthcare company dedicated to improving cancer detection through innovative technology. It focuses on the development of CancerSEEK, a liquid biopsy test that analyzes genomic mutations in tumor DNA and protein markers in plasma to identify multiple types of cancer at their earliest stages, often before symptoms become apparent. Founded in 2018 and headquartered in Cambridge, Massachusetts, with an additional office in Baltimore, Maryland, Thrive aims to integrate early cancer detection into routine medical care. The company was previously known as Thrive Sciences Inc. and has been a subsidiary of Exact Sciences Corporation since early 2021. Thrive was launched with support from various investors, including Third Rock Ventures and Section 32, reflecting a strong commitment to advancing cancer diagnostics.
Olema Oncology is a clinical-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of therapies for women's cancers, particularly focusing on estrogen receptor-positive breast cancer. The company's lead candidate, OP-1250, is an estrogen receptor antagonist and selective degrader, currently undergoing Phase 1/2 clinical trials for the treatment of metastatic or locally advanced, estrogen receptor-positive, and human epidermal growth factor receptor 2-negative breast cancer. Olema Oncology aims to innovate targeted therapies by leveraging its expertise in endocrine-driven cancers and mechanisms of acquired resistance. The company seeks to enhance treatment options for both pre- and post-menopausal women with breast cancer, striving to transform the standard of care with more effective and convenient therapies. Founded in 2006 and headquartered in San Francisco, California, Olema was previously known as CombiThera, Inc. and rebranded in 2009.
BioAtla, Inc. is a clinical-stage biopharmaceutical company based in San Diego, California, focused on developing specific and selective antibody-based therapeutics for various cancers. The company's lead product candidate, BA3011, is a conditionally active biologic (CAB) antibody-drug conjugate aimed at treating soft tissue and bone sarcomas, non-small cell lung cancer, and other tumor types. Additionally, BioAtla is developing BA3021, a CAB ADC targeted at non-small cell lung cancer and melanoma, as well as BA3071, which is an anti-cytotoxic T-lymphocyte-associated antigen 4 antibody for various cancers including renal cell carcinoma and bladder cancer. Utilizing proprietary platforms for antibody discovery and optimization, BioAtla aims to create safer and more effective cancer treatments by enhancing selectivity for tumor tissues while minimizing effects on normal tissues. The company holds over 150 issued patents and applications related to its innovative therapeutic approaches, which have the potential to address previously untreatable cancers.
Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutics for autoimmune and neurodegenerative diseases. It focuses on the treatment of body, brain, and eye disorders. The company’s C1q is an initiating molecule of the classical complement pathway that targets distinct disease processes, such as antibody-mediated autoimmune disease and complement-mediated neurodegeneration. Its product candidates include ANX005, which has completed Phase 1b clinical trials to treat patients with guillain- barré syndrome; and ANX007, which has completed Phase 1b clinical trials to treat patients with glaucoma. The company’s candidates also comprise ANX005 that has completed preclinical trials to treat patients with warm autoimmune hemolytic anemia, Huntington's disease, and amyotrophic lateral sclerosis; ANX007, which has completed preclinical trials for the treatment of geographic atrophy; and ANX009 that has completed preclinical trials for the treatment of systemic autoimmune diseases. The company was founded in 2011 and is headquartered in South San Francisco, California.
Cybin is a biopharmaceutical company dedicated to developing safe and effective therapeutics using psychedelic and medicinal mushrooms. The company focuses on creating psilocybin-based products in regions where such substances are permitted, while also conducting clinical studies across North America and other areas through collaborations with academic and institutional partners. Cybin's efforts encompass the advancement of psychedelic-based therapies, innovative delivery mechanisms, and the development of novel compounds aimed at addressing a range of mental health issues, including various psychiatric and neurological conditions.
Shattuck Labs, Inc., a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company’s lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian cancer. It also holds a collaboration agreement with Takeda Pharmaceuticals to develop SL-279252 that is in Phase 1 clinical trial in patients with advanced solid tumors and lymphoma. The company was founded in 2016 and is headquartered in Austin, Texas.
Mereo is based in London and was founded in March 2015 to fund and develop novel, innovative specialist focused products from large pharmaceutical or biotechnology companies. Pharmaceutical companies face increasingly difficult choices in the allocation of internal resources to their drug development programs. With significant P&L constraints and rich pipelines it has become increasingly difficult for many companies to fully fund and advance development all of their drug candidates, especially beyond Phase 2. Mereo has been formed to take advantage of the global pharmaceutical industry's drive for creative ways to progress their clinical development pipelines. Mereo has acquired an initial mid-late stage portfolio of three exceptionally well characterised novel products for the treatment of diseases with considerable unmet medical need from Novartis Pharmaceuticals. Each of these programmes has a comprehensive dataset for both pre-clinical and proof-of-concept clinical studies. Additional product opportunities are under evaluation. Mereo's focus is the development of innovative medicines that have the potential to significantly transform the lives of patients suffering from rare and other specialised conditions around the world. To do this, the Company depends on the combination of its team's expertise in selecting and acquiring product opportunities, creating value in the development pipeline and structuring creative transactions. Mereo's internal expertise is complemented by a unique partnership with a leading global CRO, ICON. Mereo combines the operational discipline and efficiency of a small company with the financial resources to conduct comprehensive clinical studies. Mereo will rapidly progress each of the products through further value inflection points before partnering or divesting its products. The Company also has the option to directly commercialise products, for example in orphan disease indications.
Everest Medicines Limited, a clinical-stage biopharmaceutical company, focuses on licensing, developing, and commercializing therapies for addressing critical unmet medical needs in Greater China and other Asia Pacific markets. It has a portfolio of eight clinical-stage drug candidates for the treatment of oncology, immunology, cardio-renal disease, and infectious diseases. The company was founded in 2017 and is headquartered in Shanghai, China.
Iteos Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for cancer patients. Its product pipeline includes EOS-850, a small molecule antagonist of the adenosine A2a receptor that is an open-label Phase 1/2a clinical trial in adult patients; and EOS-448, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1/2a clinical trial. The company was founded in 2011 and is headquartered in Cambridge, Massachusetts.
Kymera Therapeutics is a biopharmaceutical company based in Watertown, Massachusetts, established in 2015. It specializes in targeted protein degradation, developing innovative small molecule therapeutics that selectively degrade proteins associated with various diseases by utilizing the body's natural protein degradation mechanisms. The company is advancing several therapeutic programs, including the IRAK4 program aimed at treating immunology-inflammation diseases such as hidradenitis suppurativa, atopic dermatitis, and rheumatoid arthritis. Additionally, it is developing the IRAKIMiD program for MYD88-mutated diffuse large B cell lymphoma and the STAT3 program for hematologic malignancies and solid tumors, as well as autoimmune diseases. Through its proprietary predictive modeling platform, Kymera Therapeutics seeks to accelerate drug discovery and address previously untreatable conditions.
Vaxcyte, formerly known as SutroVax, is a next-generation vaccine company seeking to improve global health by developing superior and novel vaccines designed to prevent or treat some of the most common and deadly infectious diseases worldwide. The Company’s cell-free protein synthesis platform, comprising the XpressCFTM platform, exclusively licensed from Sutro Biopharma, Inc., together with Vaxcyte’s proprietary know-how, enables the design and production of protein carriers and antigens, the critical building blocks of vaccines, in ways that the Company believes conventional vaccine technologies currently cannot. In addition to its pneumococcal conjugate vaccines in development, VAX-24 and VAX-XP, Vaxcyte is leveraging its proprietary platform to advance other novel vaccines, including a prophylactic vaccine to prevent Group A Strep infections (VAX-A1) and a therapeutic vaccine to treat periodontal disease (VAX-PG).
ALX Oncology is a preclinical stage biotechnology company developing innovative immuno-oncology therapies for cancer. It is an independent, private biotechnology company. The founding of Alexo Therapeutics was based upon technology invented by Aaron Ring, K. Christopher Garcia, Kipp Weiskopf, Aron Levin, and Irving Weissman at Stanford University. This discovery involves soluble versions of signal regulatory protein-α (SIRPα) that have been engineered to bind CD47 with significantly greater affinity than natural SIRPα.1.
Bigfoot Biomedical, Inc., a health solution company, develops automated insulin delivery systems for people with Type 1 Diabetes (T1D). It develops a T1D Management System with cloud connectivity and human-centered-automation; and insulin pumps. Bigfoot Biomedical, Inc. was formerly known as SmartLoop Labs, Inc. and changed its name to in Bigfoot Biomedical, Inc. February 2015. The company was incorporated in 2014 and is based in Milpitas, California.
Aligos Therapeutics, Inc. is a clinical-stage biopharmaceutical company established in 2018 and based in South San Francisco, California. The company specializes in developing novel therapeutics aimed at addressing unmet medical needs in viral and liver diseases. Its lead candidate, ALG-010133, is a synthetic oligonucleotide currently undergoing Phase I clinical trials for chronic hepatitis B (CHB). In addition to this, Aligos is advancing several other drug candidates, including ALG-000184, a capsid assembly modulator for CHB; ALG-020572, an oligonucleotide for CHB; ALG-125097, an siRNA drug candidate for CHB; and ALG-055009, a small molecule THR-ß agonist targeting non-alcoholic steatohepatitis (NASH). The company leverages its extensive expertise in liver disease and viral hepatitis to develop targeted antiviral therapies, positioning itself as a leader in this therapeutic area.
Forma Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of novel therapeutics for treatment of rare hematologic diseases and cancers. Its core product candidates for development include FT-4202, which is Phase 1 trial for the treatment of sickle cell disease and other hemoglobinopathies; and FT-7051 for the treatment of metastatic castration-resistant prostate cancer. The company is also developing FT-2102, an oral selective small molecule investigational agent that is designed to bind to and inhibit mutated IDH1 enzymes, which is being evaluated in a Phase 2 trial for relapsed/refractory AML, as well as an exploratory Phase 1 trial for glioma; and FT-4101 and FT-8225, which are selective fatty acid synthase inhibitors. The company was founded in 2007 and is headquartered in Watertown, Massachusetts.
IGM Biosciences (Nasdaq: IGMS) is a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies. IgM antibodies have inherent properties that we believe may enable them to improve upon the efficacy and safety of IgG antibodies in multiple therapeutic applications. We have created a proprietary IgM antibody technology platform that we believe is particularly well suited for developing T cell engagers, receptor cross-linking agonists, and targeted cytokines. Our lead product candidate, IGM-2323, is a bispecific T cell engaging IgM antibody targeting CD20 and CD3, and we have initiated a Phase 1 clinical trial for the treatment of relapsed/refractory B cell Non-Hodgkin's lymphoma (NHL) patients in 2019. Our second product candidate is IGM-8444, an IgM antibody targeting Death Receptor 5 (DR5) for the treatment of patients with solid and hematologic malignancies, for which we have recently initiated a Phase 1 clinical trial. Also in our product pipeline is IGM-7354, a bispecific IgM antibody delivering interleukin-15 (IL-15) cytokines to PD-L1 expressing cells for the treatment of patients with solid and hematologic malignancies.
Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan, which is in Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. The company was incorporated in 2018 and is based in Buffalo Grove, Illinois.
Aprea Therapeutics, Inc. is a biopharmaceutical company focused on developing and commercializing cancer therapeutics that target the mutant p53 tumor suppressor protein. The lead product candidate, APR-246, is a first-in-class small molecule p53 reactivator currently in late-stage clinical development for hematologic malignancies, specifically myelodysplastic syndromes and acute myeloid leukemia. Founded in 2006 and headquartered in Boston, Massachusetts, Aprea aims to address significant unmet medical needs in cancer treatment through innovative therapies. The company is primarily backed by KDev Investments AB and other stakeholders, including Östersjöstiftelsen and Praktikerinvest, reflecting a strong investment foundation for its research and development efforts.
Black Diamond Therapeutics is a precision oncology medicine company focused on discovering and developing small molecule, tumor-agnostic therapies. The company's lead product candidate, BDTX-189, is designed to inhibit specific mutations in ErbB kinases, including the epidermal growth factor receptor. Additionally, Black Diamond is advancing a pipeline of allosteric-EGFR mutation inhibitors and other early-stage programs targeting allosteric mutations in kinases associated with cancer and rare genetic diseases. The company employs a technology platform known as Mutation-Allostery-Pharmacology, which aims to address undrugged mutations in patients with genetically defined cancers. Founded in 2014 and based in Cambridge, Massachusetts, Black Diamond Therapeutics was previously known as ASET Therapeutics until its rebranding in 2018.
Sojournix, Inc. is a clinical-stage biopharmaceutical company based in Waltham, Massachusetts, that specializes in developing novel therapies aimed at addressing women's health and neuroendocrine disorders. Founded in 2016, the company is currently focused on the development of SJX-653, a selective neurokinin-3 (NK3) antagonist designed as a non-hormonal treatment for moderate to severe vasomotor symptoms. Through its innovative approach, Sojournix seeks to enhance the quality of life for patients affected by these conditions.
Akero Therapeutics is a clinical-stage biotechnology company based in South San Francisco, California, focused on developing treatments for serious metabolic diseases, particularly nonalcoholic steatohepatitis (NASH). Founded in 2017, the company aims to address high unmet medical needs associated with NASH, a condition characterized by liver inflammation and damage that can lead to severe complications. Akero's lead product candidate, AKR-001, is a long-acting Fc fusion modified FGF21 protein currently undergoing Phase IIa clinical trials. This candidate is designed to restore metabolic balance by reducing liver fat and suppressing inflammation and fibrosis, thereby potentially halting the progression of NASH. The development of AKR-001 builds upon extensive research into FGF21 biology, positioning it as a promising treatment option in a field lacking approved therapies.
Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops novel antisense oligonucleotide medicines to treat the underlying causes of severe genetic diseases. Its lead product candidate, STK-001 used to treat Dravet syndrome, a severe and progressive genetic epilepsy. Stoke Therapeutics, Inc. has a partnership with Invitae Corporation to offer genetic testing. The company was formerly known as ASOthera Pharmaceuticals, Inc. and changed its name to Stoke Therapeutics, Inc. in May 2016. Stoke Therapeutics, Inc. was founded in 2014 and is headquartered in Bedford, Massachusetts.
4D Molecular Therapeutics is a clinical-stage gene therapy company based in Emeryville, California, that specializes in developing targeted gene therapy products using evolved adeno-associated virus vectors. The company has a diverse portfolio focusing on three main therapeutic areas: ophthalmology, cardiology, and pulmonology. Key product candidates include 4D-125, currently in a Phase I/II clinical trial for treating X-linked retinitis pigmentosa; 4D-110, in a Phase I trial for choroideremia; and 4D-310, also in a Phase I/II trial for Fabry disease. Additionally, 4D Molecular Therapeutics is developing investigational new drug candidates such as 4D-150 for wet age-related macular degeneration and 4D-710 for cystic fibrosis lung disease. The company aims to address unmet medical needs through its innovative gene therapies.
BioNTech is a biotechnology company based in Mainz, Germany, focused on developing and commercializing innovative immunotherapies for cancer and infectious diseases. Founded in 2008, BioNTech employs advanced computational discovery and therapeutic drug platforms to create novel biopharmaceuticals. The company has a diverse oncology pipeline, which includes various product candidates in clinical trials targeting different types of cancers, such as melanoma, prostate cancer, HPV-positive head and neck cancers, triple-negative breast cancer, and ovarian cancer. Additionally, BioNTech is exploring neo-antigen specific immunotherapies and mRNA-based treatments, along with novel immunomodulators and therapies for rare diseases. The company collaborates with several major pharmaceutical firms to enhance its research and development efforts. BioNTech also operates a subsidiary in the United States, developing targeted therapies for solid tumors.
Bigfoot Biomedical, Inc., a health solution company, develops automated insulin delivery systems for people with Type 1 Diabetes (T1D). It develops a T1D Management System with cloud connectivity and human-centered-automation; and insulin pumps. Bigfoot Biomedical, Inc. was formerly known as SmartLoop Labs, Inc. and changed its name to in Bigfoot Biomedical, Inc. February 2015. The company was incorporated in 2014 and is based in Milpitas, California.